Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000902664-25-004990·LENZ Therapeutics, Inc.
Schedule 13G ownership disclosure
LENZ THERAPEUTICS INC
Common Stock, par value $0.00001 per share · CUSIP: 52635N103
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Point72 Asset Management, L.P.
Shares: 340,000.00 · Class: 1.2%
- Point72 Capital Advisors, Inc.
Shares: 340,000.00 · Class: 1.2%
- Point72 Biotech Private Investments, LLC
Shares: 1,017,751.00 · Class: 3.6%
- Differentiated Ventures Investments, LLC
Shares: 1,017,751.00 · Class: 3.6%
- 72 Investment Holdings, LLC
Shares: 1,017,751.00 · Class: 3.6%
- Steven A. Cohen
Shares: 1,357,751.00 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000902664-25-004990
- Form type
- SCHEDULE 13G/A
- Filer
- LENZ Therapeutics, Inc.
- CIK
- CIK 1815776
- Filed
- Nov 14, 2025
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13G beneficial ownership